XML 62 R37.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Segment Information (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Segment Reporting [Abstract] |
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories, Attributable to the Company's Reportable Segment | The following table presents reportable segment profit and loss, including significant expense categories, attributable to the Company's reportable segment for the periods presented:
|  | Years Ended December 31, |
|  | 2024 |  |  | 2023 |  |  | 2022 |
Revenue 1: |  |  |  |  |  |  |  |  |
Collaboration revenue |  | $ | 35,000 |  |  | $ | 370,000 |  |  | $ | 436 |
Grant revenue |  |  | 2,314 |  |  |  | 1,206 |  |  |  | 762 |
Less 2: |  |  |  |  |  |  |  |  |
Research and development expense 3 |  |  | 262,427 |  |  |  | 330,121 |  |  |  | 397,067 |
General and administrative expense 4 |  |  | 25,453 |  |  |  | 32,589 |  |  |  | 45,012 |
Collaboration expense, net |  |  | 110,250 |  |  |  | 130,250 |  |  |  | 110,250 |
Stock-based compensation expense |  |  | 86,567 |  |  |  | 81,028 |  |  |  | 97,947 |
Depreciation expense |  |  | 19,183 |  |  |  | 19,756 |  |  |  | 24,083 |
Other income, net 5 |  |  | (103,901 | ) |  |  | (71,816 | ) |  |  | (22,661 | )
Provision (benefit) for income taxes |  |  | 3,587 |  |  |  | 2,888 |  |  |  | (325 | )
Segment net income |  |  | (366,252 | ) |  |  | (153,610 | ) |  |  | (650,175 | )
Reconciliation of profit or loss: |  |  |  |  |  |  |  |  |
Adjustments or reconciling items |  |  | — |  |  |  | — |  |  |  | — |
Consolidated net loss |  |  | (366,252 | ) |  |  | (153,610 | ) |  |  | (650,175 | )
(1) Collaboration revenue for the years ended December 31, 2024, 2023 and 2022 is related to our license agreements and collaborations with Vertex, as further described in Note 8 of the notes to the consolidated financial statements included in this Annual Report on Form 10-K. Collaboration revenue is attributed to the CRISPR Therapeutics AG entity, which is domiciled in Switzerland. (2) The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM. (3) Research and development expense for the years ended December 31, 2024, 2023 and 2022 is net of $47.9 million, $46.4 million, and $54.0 million of stock-based compensation expense, respectively, and $10.3 million, $10.9 million, and $10.6 million of depreciation expense, respectively. For the year ended December 31, 2024, the Company recorded a non-cash adjustment of $4.8 million related to an option expiration which was recognized as a benefit to research and development expense. (4) General and administrative expense for the years ended December 31, 2024, 2023 and 2022 is net of $38.6 million, $34.7 million, and $44.0 million of stock-based compensation expense, respectively, and $8.9 million, $8.9 million, and $13.5 million of depreciation expense, respectively. (5) Other income, net, consists primarily of interest income on investments, as further described in Note 3 of the notes to the consolidated financial statements included in this Annual Report on Form 10-K. For the years ended December 31, 2024, 2023 and 2022, the Company recognized interest income of $104.3 million, $76.4 million, and $23.3 million, respectively.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration